Loading...
*  Market Research Reports: Hepatorenal Syndrome Global Clinical Trials Review, H1, 2012
Hepatorenal Syndrome Global Clinical Trials Review, H1, 2012 report provides data on the Hepatorenal Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatorenal Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatorenal Syndrome ...
  http://marketreportanalyst.blogspot.com/2012/05/hepatorenal-syndrome-global-clinical.html
*  The Hepatorenal Syndrome Associated with Metastatic Angiosarcoma of the Gallbladder | Annals of Internal Medicine | American...
The Hepatorenal Syndrome is defined as unexplained renal failure occurring in a patient with cirrhosis of the liver; it rarely occurs without cirrhosis. This syndrome has been reported with hemihepatectomy (1) and neoplastic disease of the liver (2). Metastatic malignancy-associated hepatorenal syndrome in patients with otherwise normal liver parenchyma has been reported previously in only three patients (2). We describe a patient who developed the hepatorenal syndrome associated with an angiosarcoma of the gallbladder that metastasized to the liver.. A 59-year-old man was admitted with a 4-week history of right upper quadrant pain, nausea, and vomiting. The patient denied alcohol ...
  http://annals.org/aim/article/695334/hepatorenal-syndrome-associated-metastatic-angiosarcoma-gallbladder
*  Smashwords - Hepatorenal Syndrome: Causes, Tests, and Treatment Options - a book by Carla Davis
Hepatorenal syndrome is a complication of severe liver diseases causing impaired renal functions in cases of advanced liver cirrhosis and severe hepatic failure. his life-threatening syndrome can usually be avoided, and is treatable in most cases. This must-have book is your guide to the essentials concerning the causes, tests and treatment options for hepatorenal syndrome.
  https://www.smashwords.com/books/view/141001
*  Download Ascites Hyponatremia And Hepatorenal Syndrome Progress In Treatment
much do the starsI you have increased omitting for! Julia Ross download ascites hyponatremia and hepatorenal syndrome installer is a other co-housing for your mac. coding on thirty tools of download ascites hyponatremia and hepatorenal syndrome progress in, she Introduces number cells to moving alternative, treatment, phenotyping, credit, and unfavoured other low treatmentEffects that aim correcting the vitamin of our procedures.
  http://patriciasyarns.com/ebook/download-ascites-hyponatremia-and-hepatorenal-syndrome%3A-progress-in-treatment
*  Hepatorenal Syndrome - Symptoms, Causes, Treatment, Prognosis
What is Hepatorenal Syndrome? Symptoms, Treatment, Causes and Prognosis. Hepatorenal Syndrome is a condition that involves a progressive form of kidney disease, common process...
  http://syndrome.org/hepatorenal-syndrome/
*  Hepatorenal syndrome. - Plasma Protein Therapeutics Association (PPTA)
Hepatorenal syndrome (HRS) is a common complication of advanced cirrhosis, characterised by renal failure and major disturbances in circulatory function. Renal failure is caused by intense vasoconstriction of the renal circulation. The syndrome is probably the final consequence of extreme underfilling of the arterial circulation secondary to arterial vasodilatation in the splanchnic vascular bed. As well as the renal circulation, most extrasplanchnic vascular beds are vasoconstricted. The diagnosis of HRS is currently based on the exclusion of other causes of renal failure. The prognosis is very poor, particularly when there is rapidly progressive renal failure (type 1). Liver transplantation is the best option in patients without contraindications to the procedure, but it is not always possible owing to the short survival expectancy. Therapies introduced during the past few years, such as vasoconstrictor drugs (vasopressin analogues, ...
  http://pptaglobal.org/plasma-products-databases/albumin/hepatology/409-hepatorenal-syndrome
*  Hepatorenal syndrome - Wikipedia
Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of rapid deterioration in kidney function in individuals with cirrhosis or fulminant liver failure. HRS is usually fatal unless a liver transplant is performed, although various treatments, such as dialysis, can prevent advancement of the condition. HRS can affect individuals with cirrhosis, severe alcoholic hepatitis, or liver failure, and usually occurs when liver function deteriorates rapidly because of a sudden insult such as an infection, bleeding in the gastrointestinal tract, or overuse of diuretic medications. HRS is a relatively common complication of cirrhosis, occurring in 18% of people within one year of their diagnosis, and in 39% within five years of their diagnosis. Deteriorating liver function is believed to cause changes in the circulation that supplies the intestines, altering blood flow and blood vessel tone ...
  https://en.wikipedia.org/wiki/Hepatorenal_syndrome
*  Pediatric Hepatorenal Syndrome - Nursing Crib
A procedure prescribed for patients is renal biopsy wherein the findings will target the cause of the renal failure. Patients with this state must be under medications that would control the blood pressure. Vasocontrictors are the drug of choice as allows the vessels once dilated to constrict in order to prevent hypotension.. Hemodialysis is also done depending on the physician's observation and the capacity of the kidneys. Although this can be traumatic for a child to undergo, it must be done. Surgical interventions are also geared in decreasing the effects of ascites such as difficulty in breathing.. A team of health officers must work hand in hand. For example, these people may be nephrologists, gastroeneterologist and surgeons. Although the prognosis on these two types of hepatorenal syndromes, compliance to the prescribed medications and treatment may matter in the long run.. ...
  http://nursingcrib.com/nursing-notes-reviewer/maternal-child-health/pediatric-hepatorenal-syndrome/
*  A Study To Confirm the Effectiveness and Safety of Terlipressin in Adults with Hepatorenal Syndrome Type 1 - Mayo Clinic
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
  http://www.mayo.edu/research/clinical-trials/cls-20358452
*  Increase in the global average temperature of more than 2 impotens?
The report also examines the role of shipping in total should play abatement dangerous climate change is widely accepted. Els impotens .increase in the global average temperature of more than 2? C to be above pre-industrial levels. It is clear, a global approach is particularly preferred. Further research further research mentioned in the report identifies an allocation methodology for countries which can be agreed upon by many nation states to, it would be a great help to the development of a global strategy .. Complications clinical guidelines - the European guidelines for the management the ascites, spontaneous bacterial peritonitis and Hepatorenal syndrome cirrhosis of the liver Released.. Estimated that 75 % of patients having ascites Western Europe and U.S. Are cirrhosis of the liver as cause. Development of ascites is an extremely common even debilitating complication to cirrhotic patients and has a huge impact on longevity and life ...
  http://www.tildawnpapercrafts.com/increase-in-the-global-average-temperature-of-more-than-2-impotens/
*  Hepatorenal Syndrome | CTD
Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention ...
  http://ctdbase.org/detail.go?type=disease&acc=MESH%3AD006530
*  lasix and hepatorenal syndrome, interactions of lasix - Форум студентов Чехии
http://hope-plan.net/hopeplan/index.php/forum/welcome-mat/123549-high-creatinine-and-lasix-furosemide-and-low-albumin#123446http://eliteteam.tf/viewtopic.php?f=16&t=427829http://forumlk.free.fr/showthread.php?s=&threadid=69026http://www.georgesadpa.co.za/wp-content/plugins/zingiri-forum/mybb/showthread.php?tid=200977http://owaza.ru/forum/56-45407-1http://willowcrossing.ucoz.com/forum/6-33449-1http://monitortipov.info/index.php/forum/welcome-mat/27133-lasix-dose-horse-quanto-lasix-assumere#27127 ...
  http://www.cz-students.ucoz.com/forum/30-77991-1
*  Orphan Therapeutics - Terlipressin & HRS
LUCASSIN® (terlipressin) is a synthetic 12-amino acid vasopressin analogue that acts via the vasopressin V1 receptor as a systemic vasoconstrictor. In Hepatorenal Syndrome (HRS) patients, the V1 mediated vasoconstriction particularly in the splanchnic area
  http://www.orphantherapeutics.com/products
*  Terlipressin (Glypressin) Drug Information - Indications, Dosage, Side Effects and Precautions
Terlipressin(Glypressin) generic is an analogue of vasopressin, prescribed for bleeding esophageal varices, septic shock, hepatorenal syndrome and in management of low blood pressure. It regulates the body's retention of water by acting to increase water absorption in the kidney.
  http://www.medindia.net/doctors/drug_information/terlipressin.htm
*  A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With...
The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when
  http://adisinsight.springer.com/trials/700252020
*  Management of patients with cirrhosis awaiting liver transplantation | Gut
The first human orthotopic liver transplantation (OLT) was performed in the early 1960s by Thomas Starzl in the USA.1 Up until then there was little to offer patients with advanced liver disease with features of decompensation such ascites, hepatorenal syndrome (HRS), hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), gastro-oesophageal variceal bleeding, and/or hepatocellular carcinoma. These patients had a sinister prognosis because only palliative and symptomatic therapy was offered. The advent of OLT as an accepted therapy for advanced liver disease completely changed this scenario offering patients a cure to their diseased liver. In the initial years, significant advances were made in refining the indications and surgical technique. Nonetheless it took several years to realise that maximally optimising the pre-transplant status of patients would translate into better post-transplant outcomes.2 The most common conditions in decompensated ...
  http://gut.bmj.com/content/early/2010/12/30/gut.2009.179937
*  Hepatorenalt syndrom - Danish National Research Database-Den Danske Forskningsdatabase
Cirrhosis, ascites and renal impairment are associated with high morbidity and mortality. The hepatorenal syndrome (HRS) is a type of renal failure that affects patients with cirrhosis and ascites. This paper provides an update on evidence-based interventions in HRS. A number of factors can precipitate HRS. The monitoring, prevention, early detection, and correct treatment of these are essential. Terlipressin combined with albumin is the first-line treatment of type 1 HRS. In type 2 HRS with refractory ascites, liver transplantation and TIPS should be considered ...
  http://www.forskningsdatabasen.dk/catalog/247075446
*  Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites - Full Text View -...
Subject who has ascites by other causes (Tbc, CHF, malignancy, or renal disease) acute severe hyponatemia : Serum Na level , 120 mmol/L and Doubt of symptom caused by hyponatremia and the case which should raise serum Na level urgently based on the investigator's judgment international normalized ratio (INR) ,3.0 serum sodium ≥135 mmol/L serum potassium , 5.5 mmol/L Creatinine ≥ 2.0 mg/dL Hepatorenal syndrome defined as 'New International Ascites Club's diagnostic criteria' systolic arterial pressure of , 80 mmHg recent myocardial infarction (, 6 month) spontaneous bacterial peritonitis gastrointestinal bleed ( ≤7 days from randomization) ongoing hepatic encephalopathy of , grade1 known hepatocellular carcinoma intractable ...
  https://clinicaltrials.gov/ct2/show/NCT01552590?recr=Open&cond=%22Hyponatremia%22&rank=12
*  Most recent papers with the keyword fluids and electrolytes in children | Read by QxMD
Ascites is a major complication of cirrhosis. There are several evidence-based articles and guidelines for the management of adults, but few data have been published in relation to children. In the case of a pediatric patient with cirrhotic ascites (PPCA), the following questions are raised: How are the clinical assessment and ancillary tests performed? When is ascites considered refractory? How is it treated? Should fresh plasma and platelets be infused before abdominal paracentesis to prevent bleeding? What are the hospitalization criteria? What are the indicated treatments? What complications can patients develop? When and how should hyponatremia be treated? What are the diagnostic criteria for spontaneous bacterial peritonitis? How is it treated? What is hepatorenal syndrome? How is it treated? When should albumin be infused? When should fluid intake be restricted? The recommendations made here are based on pathophysiology and suggest the preferred ...
  https://www.readbyqxmd.com/keyword/109755
*  Renal Fellow Network: July 2009
This post is somewhat basic but it's always good to review, right?. The FENa is one of the most commonly used tools by both nephrologists and non-nephrologists to assess the etiology of oliguric renal failure in a patient. Classically, a FENa less than 1% is consistent with pre-renal etiologies (and means that more than 99% of the Na filtered is being reabsorbed) while a FENa greater than 1% is consistent with acute tubular necrosis or other types of intrinsic renal failure. There are however some specific instances in which the FENa fails. FENa "false positives" (e.g., the FENa is less than 1% but the patient actually has intrinstic renal failure) in the folllowing conditions. Contrast nephropathy is notorious for causing a FENa less than 1% despite its not being classified as a true pre-renal etiology of renal failure. Patients with CHF or cirrhosis/hepatorenal syndrome who develop ATN with clear evidence of granular casts may still retain a FENa less than ...
  http://renalfellow.blogspot.ca/2009/07/
*  "Renal Dysfunction with Use of Nonsteroidal Anti-Inflammatory Drugs in " by Yuan Liu
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to cause renal dysfunction in healthy patients and more pronounced renal effects in patients with cirrhosis and ascites. The use of NSAIDs have been associated with hepatorenal syndrome, a serious and often fatal complication associated with acute decline in renal function in the context of cirrhosis. However, renal safety of selective cyclo-oxygenase-2 (COX-2) and non-selective COX inhibitors has not been well delineated in current research with regards to patients with cirrhosis. This literature review seeks to compare the renal safety of selective and non-selective COX inhibitors in patients with cirrhosis. Methods: A thorough multi-database search was conducted using various combinations of keywords. Each study was evaluated using the Grading of Recommendations, Assessments, Development and Evaluation (GRADE) ...
  http://commons.pacificu.edu/pa/438/
*  Reports Liver - CytoSorb
This is the first case study that confirms the successful direct removal of liver toxins, including ammonia and bile acids by the CytoSorb. In this report a 36-year-old patient with chronic viral hepatitis C and long term chronic alcohol abuse was admitted to ICU with decompensated ethanol toxic liver cirrhosis. Despite an initial attempt to stabilize the patient using an albumin infusion and multiple paracenteses the patient developed hepatorenal syndrome and subsequent dialysis dependency. During this time, an evaluation as to whether the patient could be listed for a liver transplantation was rejected. As a „last resort" therapy, CytoSorb treatment was initiated with the rationale to remove inflammation-triggering factors and liver toxins (bile acids, bilirubin, ammonia) in the context of his systemic inflammatory condition as well as his acute-on-chronic liver failure. In total two treatments with CytoSorb were carried out for 6 hours ...
  http://cytosorb-therapy.com/literature-category/case-studies-and-reports/liver/
*  Convention | The Philippine Society of Nephrology
The course was divided into two: sessions for doctors and sessions for nurses. Topics covered during the sessions for the doctors include the following: Sepsis and Acute Kidney Injury by Dr. Marie Yvette Barez and Dr. Sandra Oliveros; Electrolyte Imbalance Emergencies by Dr. Alberto Chua; Multidisciplinary Approach to Lupus in Pregnancy (A Panel Discussion) by Dr. Noel Villanueva, Dr. Tommy Bangayan, Dr. Ma. Milflordeliza Gonzaga, Dr. Victor Espino, and Dr. Dennis John Ortiga; Urinary Stone Management by Dr. Benita Padilla; Leptospirosis Guidelines by Dr. Irmingarda Gueco; Guidelines on Contrast Induced Nephropathy by Dr. Maaliddin Biruar; Crush Injury Guidelines by Dr. Noel Camique; Hepatorenal Syndrome by Dr. Ramon Liboro and Dr. Benjamin Balmores, Jr; New CPG on UTI by Dr. Marissa Alejandria; Not All Pyuria is UTI by Dr. Lynn Almazan-Gomez; and Cardiorenal Syndrome by Dr. Agnes Mejia.. Topics discussed during the sessions for the nurses included ...
  http://psn.ph/tags/convention
*  PTU-110 Reduction In Serum Sodium (na) In Patients Treated With Terlipressin For Varcieal Bleeding (vb) And Hepatorenal...
Results 60 patients were analysed (32 HRS, 28 VB). Median Na pre-treatment was 133 and 29/60 (48%) had existing hyponatraemia; 16 (27%) had Na ,125mmol/l.. Na fell in 34/60 patients (57%) and was less likely if baseline hyponatraemia existed (38% VS 74% p = 0.004). A fall of ≥5mmol/l occurred in 23%.. Median time to nadir Na was 3 days and time to recovery to pre-treatment Na was 6.5 days. No complications of hyponatremia were observed.. Patients with VB were more likely (vs HRS patients) to have any fall in Na or a ≥5mmol/l reduction (68% vs 47% p = 0.1 and 32% vs 16% p = 0.12 respectively) but failed to reach significance.. Mortality was 22% overall and a fall in Na was actually associated with reduced mortality -9% vs 34% (p = 0.01).. ...
  http://gut.bmj.com/content/63/Suppl_1/A87.2